ArticleInvestigational new drugs2021

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.

Katrina S Pedersen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.